Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTANASDAQ:FLXNNASDAQ:SDGRNASDAQ:SUPN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTACentessa Pharmaceuticals$12.27-1.5%$13.62$7.75▼$19.09$1.63B1.53628,573 shs448,803 shsFLXNFlexion Therapeutics$9.12$9.20$4.30▼$13.66$458.93M1.531.18 million shsN/ASDGRSchrödinger$23.92+0.7%$22.78$16.60▼$28.47$1.75B1.84843,068 shs908,513 shsSUPNSupernus Pharmaceuticals$31.54-2.3%$31.86$25.53▼$40.28$1.77B0.74492,648 shs423,213 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTACentessa Pharmaceuticals-5.25%+3.87%+7.69%-30.78%+41.11%FLXNFlexion Therapeutics0.00%0.00%0.00%0.00%0.00%SDGRSchrödinger-1.70%+0.85%-2.98%-0.42%+2.50%SUPNSupernus Pharmaceuticals+0.40%-0.46%+1.93%-17.21%+8.76%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCNTACentessa Pharmaceuticals3.5979 of 5 stars4.51.00.00.03.93.30.6FLXNFlexion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASDGRSchrödinger2.1848 of 5 stars3.51.00.00.02.52.50.6SUPNSupernus Pharmaceuticals3.0549 of 5 stars2.23.00.04.13.40.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTACentessa Pharmaceuticals 3.00Buy$27.00120.05% UpsideFLXNFlexion Therapeutics 0.00N/AN/AN/ASDGRSchrödinger 3.00Buy$32.8037.12% UpsideSUPNSupernus Pharmaceuticals 2.33Hold$36.0014.14% UpsideCurrent Analyst Ratings BreakdownLatest FLXN, SUPN, SDGR, and CNTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025CNTACentessa PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform ➝ Outperform$6.005/8/2025CNTACentessa PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.004/16/2025SDGRSchrödingerKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$30.00 ➝ $32.003/31/2025CNTACentessa PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$38.003/26/2025CNTACentessa PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.003/7/2025CNTACentessa PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$27.00 ➝ $27.002/27/2025SDGRSchrödingerPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$50.00 ➝ $45.002/26/2025SUPNSupernus PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$36.00 ➝ $36.002/19/2025SUPNSupernus PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$57.00 ➝ $36.00(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTACentessa Pharmaceuticals$6.85M238.46N/AN/A$2.42 per share5.07FLXNFlexion Therapeutics$85.55M5.36N/AN/A($0.34) per share-26.82SDGRSchrödinger$230.49M7.58$0.64 per share37.42$7.60 per share3.15SUPNSupernus Pharmaceuticals$668.00M2.64$1.44 per share21.83$16.87 per share1.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTACentessa Pharmaceuticals-$151.09M-$1.99N/AN/AN/AN/A-52.13%-38.01%N/AFLXNFlexion Therapeutics-$113.71M-$2.01N/AN/AN/A-100.32%N/A-44.26%N/ASDGRSchrödinger$40.72M-$2.63N/AN/AN/A-91.84%-35.77%-24.51%7/30/2025 (Estimated)SUPNSupernus Pharmaceuticals$1.32M$1.1129.4821.90N/A9.16%7.79%5.67%5/14/2025 (Estimated)Latest FLXN, SUPN, SDGR, and CNTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025SUPNSupernus Pharmaceuticals$0.37N/AN/AN/AN/AN/A5/12/2025Q1 2025CNTACentessa Pharmaceuticals-$0.35-$0.20+$0.15-$0.20N/AN/A5/7/2025Q1 2025SDGRSchrödinger-$0.81-$0.82-$0.01-$0.82$54.60 million$59.55 million3/24/2025Q4 2024CNTACentessa Pharmaceuticals-$0.38-$0.34+$0.04-$0.84N/AN/A2/26/2025Q4 2024SDGRSchrödinger-$0.35-$0.55-$0.20-$0.55$83.20 million$88.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNTACentessa PharmaceuticalsN/AN/AN/AN/AN/AFLXNFlexion TherapeuticsN/AN/AN/AN/AN/ASDGRSchrödingerN/AN/AN/AN/AN/ASUPNSupernus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTACentessa Pharmaceuticals0.1521.5221.52FLXNFlexion TherapeuticsN/A4.384.05SDGRSchrödingerN/A4.114.11SUPNSupernus PharmaceuticalsN/A2.201.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTACentessa Pharmaceuticals82.01%FLXNFlexion Therapeutics90.01%SDGRSchrödinger79.05%SUPNSupernus PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipCNTACentessa Pharmaceuticals11.59%FLXNFlexion Therapeutics9.13%SDGRSchrödinger8.60%SUPNSupernus Pharmaceuticals9.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTACentessa Pharmaceuticals200133.18 million116.56 millionOptionableFLXNFlexion Therapeutics25750.32 million45.73 millionOptionableSDGRSchrödinger79073.04 million66.59 millionOptionableSUPNSupernus Pharmaceuticals58055.99 million50.08 millionOptionableFLXN, SUPN, SDGR, and CNTA HeadlinesRecent News About These CompaniesIs the Options Market Predicting a Spike in Supernus Pharmaceuticals (SUPN) Stock?May 14 at 3:31 PM | zacks.comDZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Sells 103,501 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)May 14 at 4:57 AM | marketbeat.comCentiva Capital LP Acquires New Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)May 14 at 4:39 AM | marketbeat.comBNP Paribas Financial Markets Buys 208,552 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)May 14 at 4:11 AM | marketbeat.comSolid Earnings Reflect Supernus Pharmaceuticals' (NASDAQ:SUPN) Strength As A BusinessMay 13 at 7:31 PM | finance.yahoo.comComerica Bank Buys 15,585 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)May 13 at 3:56 AM | marketbeat.comSchonfeld Strategic Advisors LLC Invests $388,000 in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)May 13 at 3:49 AM | marketbeat.comNorthern Trust Corp Increases Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)May 13 at 3:48 AM | marketbeat.comSupernus Pharmaceuticals (SUPN) Expected to Announce Earnings on WednesdayMay 12 at 4:37 AM | americanbankingnews.comCubist Systematic Strategies LLC Increases Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)May 11 at 6:23 AM | marketbeat.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by First Trust Advisors LPMay 10, 2025 | marketbeat.comSupernus Pharmaceuticals, Inc.: Supernus Announces First Quarter 2025 Financial ResultsMay 10, 2025 | finanznachrichten.deSupernus Pharmaceuticals (SUPN) to Release Quarterly Earnings on WednesdayMay 9, 2025 | marketbeat.comLost Money on Supernus Pharmaceuticals, Inc. (SUPN)? Contact Levi & Korsinsky Regarding an Ongoing InvestigationMay 9, 2025 | accessnewswire.comSupernus Pharmaceuticals Reports 44% Increase in Qelbree® Sales and Launches ONAPGO™ in Q1 2025May 9, 2025 | nasdaq.comLevi & Korsinsky Reminds Supernus Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - SUPNMay 8, 2025 | accessnewswire.comSUPN STOCK ALERT: Levi & Korsinsky Notifies Supernus Pharmaceuticals, Inc. Investors of an Ongoing InvestigationMay 7, 2025 | accessnewswire.comSupernus Pharmaceuticals Inc (SUPN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ...May 7, 2025 | gurufocus.comSupernus projects $600M-$630M revenue for 2025 with robust growth in core productsMay 7, 2025 | msn.comSupernus Pharmaceuticals Reports Q1 2025 Earnings GrowthMay 7, 2025 | tipranks.comSupernus Pharmaceuticals, Inc. (SUPN) Q1 2025 Earnings Call TranscriptMay 7, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFLXN, SUPN, SDGR, and CNTA Company DescriptionsCentessa Pharmaceuticals NASDAQ:CNTA$12.27 -0.19 (-1.52%) As of 04:00 PM EasternCentessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.Flexion Therapeutics NASDAQ:FLXNFlexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.Schrödinger NASDAQ:SDGR$23.92 +0.16 (+0.67%) As of 04:00 PM EasternSchrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.Supernus Pharmaceuticals NASDAQ:SUPN$31.54 -0.74 (-2.29%) As of 04:00 PM EasternSupernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
